{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02033525",
      "OrgStudyIdInfo": {
        "OrgStudyId": "XCEL-MEN-01"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2011-006270-13",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Banc de Sang i Teixits",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stromal Cells for Degenerative Meniscus Injury",
      "OfficialTitle": "A Phase I-IIa Safety and Efficacy Pilot Clinical Trial of Intraarticular Administration of Autologous Mesenchymal Cells for Meniscus Injury"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2018",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 31, 2014",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "May 2, 2017",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "May 2, 2017",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "January 8, 2014",
      "StudyFirstSubmitQCDate": "January 9, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 10, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "January 8, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 9, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Banc de Sang i Teixits",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Hospital Universitari Quirón Dexeus",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Ministerio de Sanidad, Servicios Sociales e Igualdad",
            "CollaboratorClass": "OTHER_GOV"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The present proposal has the objective to assess whether the addition of autologous ex vivo expanded mesenchymal stromal cells (XCEL-M-ALPHA) to the conventional meniscal injury rehabilitation program is contributing in creating the proper healing environment for the meniscus repair. For this purpose, 20 patients will be randomized (10 per group) to one of the two treatment arms (rehabilitation + xcel-m-alpha or rehabilitation alone) . The conduction of this clinical trial will, in addition of having the aim of improving the patient's quality of life, contribute to consolidate an emerging new type of therapy which is still under development.",
      "DetailedDescription": "This is a prospective, unicentric, randomized, open-label, single-dose, two-arm, blinded assessor pilot study in which 20 patients with degenerative meniscus injury grade 3 (Crues et al.) will enter the study with the primary objective of assessing the efficacy of the treatment by VAS of pain at 12 month. Secondary objectives are to evaluate the safety and efficacy through imaging procedures and clinical questionnaires (IKDC, KOOS, Lysholm and SF-36.\n\nPatients will be randomized to one of the two treatment arms (XCEL-M-ALPHA and standard rehabilitation program or standard rehabilitation program alone). Thereafter, patients will be followed for 12 months.\n\nImaging assessment will be performed by an independent blinded radiologist."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Chronic Meniscal Injury"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Chronic Meniscal Injury",
          "Degenerative meniscus",
          "Meniscus injury",
          "Meniscal injury",
          "Mesenchymal stromal cells",
          "Mesenchymal stem cells",
          "Advanced Therapy",
          "Bone marrow"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "20",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "XCEL-M-ALPHA and standard rehabilitation",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: XCEL-M-ALPHA and standard rehabilitation"
              ]
            }
          },
          {
            "ArmGroupLabel": "standard rehabilitation",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Standard rehabilitation program",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Rehabilitation"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "XCEL-M-ALPHA and standard rehabilitation",
            "InterventionDescription": "Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "XCEL-M-ALPHA and standard rehabilitation"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "XCEL-M-ALPHA"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Rehabilitation",
            "InterventionDescription": "Standard rehabilitation program",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "standard rehabilitation"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "VAS for pain",
            "PrimaryOutcomeDescription": "Visual analogue scale (VAS) for pain at 12 month follow-up.",
            "PrimaryOutcomeTimeFrame": "12 month"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Safety",
            "SecondaryOutcomeDescription": "Safety will be assessed by collecting adverse events, physical exam, laboratory tests, and vital signs.",
            "SecondaryOutcomeTimeFrame": "12 month"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy by MRI",
            "SecondaryOutcomeDescription": "Efficacy will be assessed by qualitative and quantitative changes of the meniscus and articular cartilage by imaging procedures (MRI) at 6 and 12 month follow-up.",
            "SecondaryOutcomeTimeFrame": "6 and 12 month"
          },
          {
            "SecondaryOutcomeMeasure": "VAS for pain",
            "SecondaryOutcomeDescription": "Visual analogue scale (VAS) for pain at 1, 3 and 6 month follow-up.",
            "SecondaryOutcomeTimeFrame": "1, 3 and 6 month"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy by clinical questionnaires",
            "SecondaryOutcomeDescription": "IKDC, KOOS and Lysholm functionality test and SF-36 quality of life at 3, 6 and 12 month follow-up",
            "SecondaryOutcomeTimeFrame": "3, 6 and 12 month"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatient between 40 and 60 years of age\nDegenerative meniscus injury grade 3 (Crues et al.)\nIndication of conservative treatment\nNormal alignment of the knee (between 3º varus and 10 º valgus)\nPatient is able to follow a rehabilitation program\nInformed consent given by the patient in writing\nPatient is able to understand the trial.\n\nExclusion Criteria:\n\nTraumatic meniscus injury\nSurgical intervention to the affected knee\nLocal or systemic infection\nIntraarticular treatment of the affected knee with steroids or hyaluronic acid within the past 3 months\nSignificant abnormal laboratory tests that contraindicates participation in the trial.\nPregnant women or intend to become pregnant or breast-feeding\nNeoplastic process within the previous 5 years or without complete remission.\nThe patient is wearing a pacemaker, allergy to contrast, severe renal insufficiency or any other condition that contraindicates the magnetic resonance using contrast.\nOther pathologic conditions or circumstances that difficult participation in the study according to medical criteria\nLegally dependant patient.\nThe patient does not accept to be followed-up for a period that could exceed the clinical trial length",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "40 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Joan Carles Monllau, MD, PhD",
            "OverallOfficialAffiliation": "ICATME-Hospital Quiron Dexeus",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "ICATME-Hospital Quiron Dexeus",
            "LocationCity": "Barcelona",
            "LocationZip": "08028",
            "LocationCountry": "Spain"
          }
        ]
      }
    },
    "ReferencesModule": {
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Blood and tissue bank of Catalonia",
            "SeeAlsoLinkURL": "http://www.bancsang.net/en/index.html"
          },
          {
            "SeeAlsoLinkLabel": "Fundación ICATME (Spanish only)",
            "SeeAlsoLinkURL": "http://www.icatme.com/"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000014947",
            "ConditionMeshTerm": "Wounds and Injuries"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M16837",
            "ConditionBrowseLeafName": "Wounds and Injuries",
            "ConditionBrowseLeafAsFound": "Injury",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC26",
            "ConditionBrowseBranchName": "Wounds and Injuries"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}